This page contains brief information about lenvatinib mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lenvatinib mesylate is approved to be used alone or with other drugs to treat:
- Hepatocellular carcinoma (a type of liver cancer). It is used as first-line treatment in patients whose disease cannot be removed by surgery.
- Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used with everolimus in patients who have already received angiogenesis inhibitor therapy.
- Thyroid cancer in certain patients with progressive, recurrent, or metastatic disease that does not respond to treatment with radioactive iodine.
Lenvatinib mesylate is also being studied in the treatment of other types of cancer.
More About Lenvatinib Mesylate
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Lenvatinib Mesylate – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
